Beijing Wantai Biological Pharmacy Enterprise (SHA:603392), a Chinese vaccine developer and manufacturer of medical products, plans to start a large trial of its nasal spray-based COVID-19 vaccine candidate next month, Reuters news agency reported on Thursday.
According to an entry posted on the Chinese Clinical Trial Registry on Wednesday, the company aims to recruit 40,000 adults for the Phase III clinical trial. Participants would be given two doses of the Beijing Wantai vaccine candidate or a placebo vaccine at a two-week interval.
The record did not specify in how many countries Beijing Wantai will run the trial. However, it indicated that an ethics committee in the Philippines had approved the study.
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma